As PSMA PET/CT has greater diagnostic accuracy for detection of metastatic disease in comparison to conventional imaging techniques (92% vs 65% in the proPSMA-study [8]), it may have a substantial influence on management decisions for patients with BCR [26], [27]. The gene discussed is FOLH1; the disease is metastatic neoplasm.